Do you know someone with a diagnosis of Frontotemporal Dementia?

Researchers are evaluating the use of memantine (Namenda®) in those with a diagnosis of frontotemporal dementia (FTD). Memantine is currently an FDA approved treatment for Alzheimer’s disease. Evidence from studies of persons with Alzheimer’s disease suggests memantine may reduce damage to brain cells and therefore may also be effective in people with FTD. This study is designed to evaluate the safety and tolerability of memantine in FTD and to evaluate whether memantine will slow the rate of decline in thinking and in problem behaviors in FTD.

Participation Includes:
- Six visits to our clinic over a period of 30 weeks
- Taking memantine or a placebo (“sugar pill”) twice daily
- Two blood draws throughout the study
- Testing of memory and thinking skills
- Physical and neurological examinations
- Compensation of study related expenses (i.e., travel)

Study Eligibility Includes:
- Diagnosis of FTD
- Not currently taking a prescription of memantine, donepezil (Aricept®), rivastigmine (Exelon®), or galantamine (Razadyne®)
- Between 40 and 80 years of age
- A friend or relative to assist with medication and study visits

For more information or to volunteer, contact:

Kristine Lipowski, Study Coordinator
(312) 503-2486
Cognitive Neurology and Alzheimer’s Disease Center
of the Northwestern University Feinberg School of Medicine

Trial Sponsor: Forest Research Institute
IRB # 2675-003